Akums Drugs and Pharmaceuticals Limited — Important, 14-02-2025: General Updates

Akums Drugs and Pharmaceuticals Limited has secured a patent for its "Benzalkonium Chloride-Free Ophthalmic Formulation," aimed at reducing elevated intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension. This innovative formulation, free from preservatives that can cause irritation, enhances patient comfort, particularly for those requiring long-term treatment. The patent is valid for 20 years, highlighting Akums' commitment to advancing ophthalmic solutions. This development is significant given that glaucoma affects approximately 11.9 million individuals in India, emphasizing the potential market for this safer and more effective therapy. Investors should view this achievement as a positive outlook for the company’s innovation trajectory and growth potential in the ophthalmic sector.